The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Target 2035: probing the human proteome
Open accessAbstract
Biomedical scientists tend to focus on only a small fraction of the proteins encoded by the human genome despite overwhelming genetic evidence that many understudied proteins are important for human disease. One of the best ways to interrogate the function of a protein and to determine its relevance as a drug target is by using a pharmacological modulator, such as a chemical probe or an antibody. If these tools were available for most human proteins, it should be possible to translate the tremendous advances in genomics into a greater understanding of human health and disease, and catalyze the creation of innovative new medicines. Target 2035 is a global federation for developing and applying new technologies with the goal of creating chemogenomic libraries, chemical probes, and/or functional antibodies for the entire proteome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
The International HapMap Project
†The International HapMap Consortium, Genotyping centres: Baylor College of Medicine and ParAllele BioScience, Gibbs, R. A., Belmont, J. W., Hardenbol, P., Willis, T. D., Yu, F., Chinese HapMap Consortium, Yang, H., Ch'ang, L.-Y., et al. (2003) · Nature · doi:10.1038/nature02168 · Cited by 6,057
Barabási, A.-L., & Bonabeau, E. (2003) · Scientific American · doi:10.1038/scientificamerican0503-60 · Cited by 2,494
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
The BioPlex network: a systematic exploration of the human interactome
Huttlin, E. L., Ting, L., Bruckner, R. J., Gebreab, F., Gygi, M. P., Szpyt, J., Tam, S., Zarraga, G., Colby, G., Baltier, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.043 · Cited by 1,425
The Human Genome Project: Lessons from Large-Scale Biology
Collins, F. S., Morgan, M., & Patrinos, A. (2003) · Science · doi:10.1126/science.1084564 · Cited by 1,284
Ultra-large library docking for discovering new chemotypes
Lyu, J., Wang, S., Balius, T. E., Singh, I., Levit, A., Moroz, Y. S., O’Meara, M. J., Che, T., Algaa, E., Tolmachova, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0917-9 · Cited by 998
The promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
Self-citationDNA-encoded chemistry: enabling the deeper sampling of chemical space
Goodnow, R. A., Dumelin, C. E., & Keefe, A. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.213 · Cited by 621
Edwards, A. M., Isserlin, R., Bader, G. D., Frye, S. V., Willson, T. M., & Yu, F. H. (2011) · Nature · doi:10.1038/470163a · Cited by 411
Self-citationUnexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
The human proteome project: current state and future direction
Legrain, P., Aebersold, R., Archakov, A., Bairoch, A., Bala, K., Beretta, L., Bergeron, J., Borchers, C. H., Corthals, G. L., Costello, C. E., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.009993 · Cited by 352
Large-scale investigation of the reasons why potentially important genes are ignored
Stoeger, T., Gerlach, M., Morimoto, R. I., & Nunes Amaral, L. A. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2006643 · Cited by 261
Deshaies, R. J. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1887 · Cited by 162
Glimmers in illuminating the druggable genome
Rodgers, G., Austin, C., Anderson, J., Pawlyk, A., Colvis, C., Margolis, R., & Baker, J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.252 · Cited by 126
neXtProt: Organizing Protein Knowledge in the Context of Human Proteome Projects
Gaudet, P., Argoud-Puy, G., Cusin, I., Duek, P., Evalet, O., Gateau, A., Gleizes, A., Pereira, M., Zahn-Zabal, M., Zwahlen, C., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr300830v · Cited by 124
Roberts, A. M., Ward, C. C., & Nomura, D. K. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.08.003 · Cited by 108
Life cycles of successful genes
Hoffmann, R., & Valencia, A. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(02)00014-8 · Cited by 69
Temporal patterns of genes in scientific publications
Pfeiffer, T., & Hoffmann, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701315104 · Cited by 64
Research works printed but not linked: 27
- Maglott, 2007, Entrez Gene: gene-centered information at NCBI, Nucleic Acids Res., 35, D26, 10.1093/nar/gkl993 · DOI · Paper page
- Perc, 2014, The Matthew effect in empirical data, J. R. Soc. Interface, 11, 10.1098/rsif.2014.0378 · DOI · Paper page
- Barabási, 2009, Scale-free networks: a decade and beyond, Science, 325, 412, 10.1126/science.1173299 · DOI · Paper page
- Uhlén, 2005, A human protein atlas for normal and cancer tissues based on antibody proteomics, Mol. Cell. Proteomics, 4, 1920, 10.1074/mcp.M500279-MCP200 · DOI · Paper page
- HUPO, 2010, A gene-centric human proteome project, Mol. Cell. Proteomics, 9, 427, 10.1074/mcp.H900001-MCP200 · DOI
- Omenn, 2018, Progress on identifying and characterizing the human proteome: 2018 metrics from the HUPO Human Proteome Project, J. Proteome Res., 17, 4031, 10.1021/acs.jproteome.8b00441 · DOI
- Paik, 2012, The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome, Nat. Biotechnol., 30, 221, 10.1038/nbt.2152 · DOI · Paper page
- Marko-Varga, 2013, A first step toward completion of a genome-wide characterization of the human proteome, J. Proteome Res., 12, 1, 10.1021/pr301183a · DOI
- Paik, 2018, Launching the C-HPP neXt-CP50 pilot project for functional characterization of identified proteins with no known function, J. Proteome Res., 17, 4042, 10.1021/acs.jproteome.8b00383 · DOI
- Rual, 2005, Towards a proteome-scale map of the human protein–protein interaction network, Nature, 437, 1173, 10.1038/nature04209 · DOI · Paper page
- Rolland, 2014, A proteome-scale map of the human interactome network, Cell, 159, 1212, 10.1016/j.cell.2014.10.050 · DOI · Paper page
- Cafarelli, 2017, Mapping, modeling, and characterization of protein–protein interactions on a proteomic scale, Curr. Opin. Struct. Biol., 44, 201, 10.1016/j.sbi.2017.05.003 · DOI
- Zhang, 2018, Structure and protein interaction-based gene ontology annotations reveal likely functions of uncharacterized proteins on human chromosome 17, J. Proteome Res., 17, 4186, 10.1021/acs.jproteome.8b00453 · DOI
- Bredel, 2004, Chemogenomics: an emerging strategy for rapid target and drug discovery, Nat. Rev. Genet., 5, 262, 10.1038/nrg1317 · DOI · Paper page
- Oprea, 2018, Far away from the lamppost, PLoS Biol., 16, 10.1371/journal.pbio.3000067 · DOI
- Fedorov, 2010, The (un)targeted cancer kinome, Nat. Chem. Biol., 6, 166, 10.1038/nchembio.297 · DOI · Paper page
- Akinjiyan, 2017, Lead discovery and chemical biology approaches targeting the ubiquitin proteasome system, Bioorg. Med. Chem. Lett., 27, 4589, 10.1016/j.bmcl.2017.08.058 · DOI
- Robertson, 1980, Biology in the 1980s, plus or minus a decade, Nature, 285, 358, 10.1038/285358a0 · doi:10.1038/285358a0
- Müller, 2018, Donated chemical probes for open science, eLife, 7, e34311, 10.7554/eLife.34311 · DOI
- Patel, 2014, Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery, Prog. Biophys. Mol. Biol., 116, 92, 10.1016/j.pbiomolbio.2014.08.004 · DOI
- O’Connell, 2014, Solution-based indirect affinity selection mass spectrometry—a general tool for high-throughput screening of pharmaceutical compound libraries, Anal. Chem., 86, 7413, 10.1021/ac500938y · DOI
- Jensen, 2015, CETSA: a target engagement assay with potential to transform drug discovery, Future Med. Chem., 7, 975, 10.4155/fmc.15.50 · DOI
- Barelier, 2014, Increasing chemical space coverage by combining empirical and computational fragment screens, ACS Chem. Biol., 9, 1528, 10.1021/cb5001636 · DOI
- Campos, 2019, The importance of synthetic chemistry in the pharmaceutical industry, Science, 363, eaat0805, 10.1126/science.aat0805 · DOI · Paper page
- Sachidanandam, 2001, A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, 409, 928, 10.1038/35057149 · DOI · Paper page
- Edwards, 2017, A trust approach for sharing research reagents, Sci. Transl. Med., 9, eaai9055, 10.1126/scitranslmed.aai9055 · doi:10.1126/scitranslmed.aai9055
- Scheer, 2019, A chemical biology toolbox to study protein methyltransferases and epigenetic signaling, Nat. Commun., 10, 10.1038/s41467-018-07905-4 · DOI
Cited by
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
“Starting from a well characterized small molecule provides a distinct advantage and as more become available via the Target 2035 initiative (Carter et al., 2019), the rate and ease of PROTAC development will no doubt increase.”
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2021) · SLAS Discovery · doi:10.1177/2472555220965528 · Cited by 380
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
Kuljanin, M., Mitchell, D. C., Schweppe, D. K., Gikandi, A. S., Nusinow, D. P., Bulloch, N. J., Vinogradova, E. V., Wilson, D. L., Kool, E. T., Mancias, J. D., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00778-3 · Cited by 305
Opportunities and challenges in translational science
Austin, C. P. (2021) · Clinical and Translational Science · doi:10.1111/cts.13055 · Cited by 188
Metadata
- Authors
- Carter, A. J., Kraemer, O., Zwick, M., Mueller-Fahrnow, A., Arrowsmith, C. H., & Edwards, A. M.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 24
- Issue
- 11
- Pages
- 2111-2115
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2954028792
- Cited by
- 165
- References
- 19
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- AbbVie
- Bayer
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Eshelman Institute for Innovation
- Ontario Genomics Institute (OGI-055)
- Innovative Medicines Initiative (115766)
- Janssen
- Merck KGaA
- MSD
- Novartis Pharma AG
- Ontario Ministry of Research, Innovation and Science
- Pfizer
- FAPESP
- Takeda
- The Wellcome Trust
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.